KRYS
Krystal Biotech Surpasses Expectations as VYJUVEK Drives Record 2025 Revenue and International Expansion
Krystal Biotech, Inc. (NASDAQ: KRYS), a leader in redosable gene therapies, today announced record-breaking financial results for the fourth quarter…
Krystal Biotech: Flawless Vyjuvek Launch
Executive summary Krystal Biotech has successfully transitioned into a commercial-stage biotechnology powerhouse following the landmark regulatory approval and rapid market…